Publications from MSIF and other stakeholders in support of work on access to MS healthcare.
We look into these in more detail to understand how the treatment decisions are made by regulators.
Researchers in Israel have published the results of a small study exploring how well the Pfizer-BioNtech COVID-19 vaccine protects people with MS taking cladribine, fingolimod or ocrelizumab.
EMA conducts safety review of alemtuzumab (Lemtrada)
Clinical trials are rarely conducted in children with MS, but a new study has shown that new generation medications are safe to use in children with MS.